Physician profile
Plakyil Joseph
NPI 1821070418
$9,037.51
in general payments reported to CMS, 2019-2025
44 companies · $75.00 in 2025
The $75.00 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,541 · 2020: $409 · 2021: $41.08 · 2022: $86.10 · 2023: $297 · 2024: $588 · 2025: $75.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.74 |
| Education | $122.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,536.98 | 2019-2024 | |
| Janssen Biotech, INC. | $430.43 | 2019-2023 | Rybrevant |
| Astrazeneca Pharmaceuticals LP | $263.73 | 2019-2025 | Imfinzi, Epanova, Lynparza |
| Eisai INC. | $248.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $239.90 | 2019-2024 | Keytruda, Welireg |
| Celgene Corporation | $217.88 | 2019-2021 | |
| Pfizer INC. | $174.22 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $168.26 | 2019 | |
| Incyte Corporation | $137.66 | 2019 | |
| Genentech USA, INC. | $120.66 | 2019 | |
| Dova Pharmaceuticals | $118.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.94 | 2019-2020 | |
| Taiho Oncology, INC. | $85.73 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $78.67 | 2019-2024 | Provenge |
| Mirati Therapeutics, INC. | $70.86 | 2023-2024 | Krazati |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Plakyil Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.